Indications
Osteoporosis
This is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus:
Treatment of moderate to severe vasomotor symptoms associated with menopause
Prevention of postmenopausal osteoporosis
Dosage And Administration
This Information Is Not Available. Ask Your Doctor Or Pharmacist.
Side Effects
In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence ≥5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain.
Precautions And Warnings
Women taking this tablet should not take progestins, additional estrogens or additional estrogen agonist/antagonists
Cardiovascular disorders, including venous thromboembolism, pulmonary embolism, stroke, and retinal vascular thrombosis
Malignant neoplasms, including endometrial cancer, breast cancer, and ovarian cancer
Estrogens increase the risk of gallbladder disease
Discontinue estrogen if loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs
Monitor thyroid function in women on thyroid replacement therapy
Pregnancy And Lactation
Pregnancy Category X. This tablet must not be used in women who are or may become pregnant. No studies were performed on animals to evaluate the effects on reproduction with conjugated estrogens/bazedoxifene. This tablet should not be used by lactating women. It is not known whether this drug is excreted in human milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving conjugated estrogens. Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the milk